Clinical Trials Logo

Pancreatic Cancer Stage IV clinical trials

View clinical trials related to Pancreatic Cancer Stage IV.

Filter by:

NCT ID: NCT04137822 No longer available - Pancreatic Cancer Clinical Trials

Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer

Start date: n/a
Phase:
Study type: Expanded Access

An Expanded Access Program for IMM-101 for patients with advanced pancreatic cancer.

NCT ID: NCT03697564 Suspended - Clinical trials for Pancreatic Cancer Stage IV

Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial).

Start date: October 31, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if the combination of nivolumab + cabiralizumab + gemcitabine can give prolonged disease control in patients with advanced pancreatic cancer compared to gemcitabine alone. Cabiralizumab is an antibody (a type of protein) that binds to a molecule called CSF-1r. CSF-1r is a molecule present on different types of cells in your immune system that controls parts of your immune system. Blocking CSF-lr could potentially stop the cancer cells which it appears on from escaping the immune system, which could then act to kill the cancer cells. Nivolumab is an anti-PD-1 antibody that boost the body's immune system. It works by attaching to and blocking a molecule on white blood cells called PD-1. PD-1 is a protein that is present on different types of cells in your immune system and controls parts of your immune system by shutting it down. Antibodies that block PD-1 can potentially prevent PD-1 from shutting down the immune system, thus allowing immune cells to recognize and destroy cancer cells. Gemcitabine is currently used to treat advanced or metastasized (spread) pancreatic cancer. It is used in patients whose disease cannot be removed by surgery and who have already been treated with other chemotherapy

NCT ID: NCT03412799 Completed - Clinical trials for Stage IV Pancreatic Cancer

Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Start date: June 4, 2018
Phase: Phase 1
Study type: Interventional

This is an open-label phase 1A/1B study to assess the safety, tolerability and pharmacokinetics of SBP-101 when combined with nab-paclitaxel and gemcitabine in subjects with previously untreated metastatic pancreatic ductal adenocarcinoma and to identify a recommended phase 2 dose. The study will also assess preliminary efficacy of the 3-drug treatment combination.

NCT ID: NCT03252808 Active, not recruiting - Clinical trials for Pancreatic Cancer Stage IV

Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients With Unresectable Pancreatic Cancer.

Start date: September 25, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the recommended dose of TBI-1401(HF10) treatment in combination with chemotherapy (Gemcitabine + Nab-paclitaxel or TS-1) in patients with stage III or IV unresectable pancreatic cancer.

NCT ID: NCT03236883 Recruiting - Clinical trials for Pancreatic Cancer Stage IV

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Pancreatic Cancer

HST
Start date: April 2016
Phase: Phase 1
Study type: Interventional

To evaluate the safety and efficacy of non-myeloablative hematopoietic stem cell transplantation in the treatment of pancreatic cancer.

NCT ID: NCT02981641 Recruiting - Clinical trials for Pancreatic Cancer Stage IV

IORT Versus CCRT for Pancreatic Cancer

IVCPC
Start date: December 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to find the better radiation therapy between intraoperative radiotherapy (IORT) and concurrent chemoradiotherapy (CCRT).